Prescribing trends of glaucoma drugs in six major cities of China from 2013 to 2017

Autoři: Lingyan Yu aff001;  Kai Ding aff001;  Lifang Luo aff001;  Zhenwei Yu aff002
Působiště autorů: Department of Pharmacy, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China aff001;  Department of Pharmacy, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China aff002
Vyšlo v časopise: PLoS ONE 15(1)
Kategorie: Research Article
doi: 10.1371/journal.pone.0227595



To evaluate the prescribing trends of glaucoma drugs in six major cities of China from 2013 to 2017.


A descriptive analysis using pharmacy prescription data was conducted. Outpatient prescription data was extracted from the Hospital Prescription Analysis Cooperative Project. Prescribing patterns, trends of visits, and corresponding expenditures for glaucoma medications were analyzed.


A total of 84297 ambulatory prescriptions were included in the current study. Visits by glaucoma patients increased from 13808 in 2013 to 20060 in 2017. Over the same period, the yearly expenditure for glaucoma drugs increased from 2.33 million to 3.95 million Chinese Yuan (CNY). Among all the six classes of glaucoma drugs (prostaglandin analogues, carbonic anhydrase inhibitors, α-receptor agonists, β-receptor antagonists, cholinergic agonists and fixed combinations), β-receptor antagonists were the most commonly prescribed in 2013, accounting for 34.3% of patients, but gradually decreased to 27.1% in 2017. Prostaglandin analogues became the most frequently prescribed drugs in 2017, accounting for 30.2% of the visits. Prostaglandin analogues are the most expensive and yielded a total expenditure of 2.34 million CNY in 2017, followed by carbonic anhydrase inhibitors, α-receptor agonists, β-receptor antagonists, fixed combinations, and cholinergic agonists. Combination therapy became increasingly prescribed in 2017.


Glaucoma prescribing practices exhibited substantial changes over the study period. The number of glaucoma prescriptions continuously increased from 2013 to 2017, leading to increased prescription costs. These findings implied a similar trend observed in previous studies, as well as recommendations in the appropriate guidelines.

Klíčová slova:

Adverse reactions – Drug therapy – Glaucoma – Cholinergics – Intraocular pressure – Outpatients – Prostaglandin – Carbonic anhydrases


1. Gupta D, Chen PP. Glaucoma. Am Fam Physician. 2016, 93:668–674 27175839

2. Quigley H, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006, 90:262–267. 16488940

3. Song P, Wang J, Bucan K, Theodoratou E, Rudan I, Chan K, et al. National and subnational prevalence and burden of glaucoma in China: A systematic analysis. J Glob Health. 2017,7:1–18.

4. Boland MV, Ervin AM, Friedman DS, Jampel HD, Hawkins BS, Vollenweider D, et al. Comparative effectiveness of treatments for open-angle glaucoma: A systematic review for the U.S. preventive services task force. Ann Intern Med. 2013, 158:271–279. 23420235

5. National Institute for Health and Care Excellence. Glaucoma: diagnosis and management. 2017.

6. Weinreb RN, Aung T, Medeiros FA. The Pathophysiology and Treatment of Glaucoma: a review. JAMA. 2014, 311:1901–1911. 24825645

7. Sambhara D, Aref AA. Glaucoma management: Relative value and place in therapy of available drug treatments. Ther Adv Chronic Dis.2014, 5:30–43. 24381726

8. Yu L, Chen X, Yu Z. Trends of antidementia drugs use in outpatients with Alzheimer’s disease in six major cities of China: 2012–2017. Int Clin Psychopharmacol. 2019, 34:312–316. doi: 10.1097/YIC.0000000000000278 31274694

9. Han G, Yu Z, Ma K. Current status of parenteral nutrition and enteral nutrition application: an assessment of nutritional prescriptions from 59 hospitals in the People ‘ s Republic of China. Ther Clin Risk Manag. 2015,11:201–207. 25709462

10. Heng JS, Wormald R, Khaw PT. Geographical variation in glaucoma prescribing trends in England 2008–2012: An observational ecological study. BMJ Open. 2016,6:1–10.

11. Song W, Shan L, Cheng F, Fan P, Zhang L, Qu W, et al. Prevalence of glaucoma in a rural northern China adult population: A population-based survey in Kailu County, Inner Mongolia. Ophthalmology. 2011, 118:1982–1988. 21684607

12. Rotchford AP, Hughes J, Agarwal PK, Tatham AJ. Prevalence of treatment with glaucoma medication in Scotland, 2010–2017. Br J Ophthalmol 2019, 0:1–5.

13. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. Ophthalmology. 2014,121:2081–2090. 24974815

14. Sakamoto M, Kitamura K, Kashiwagi K. Changes in Glaucoma Medication during the Past Eight Years and Future Directions in Japan Based on an Insurance Medical Claim Database. J Ophthalmol 2017, 2017:1–6.

15. Levkovitch-Verbin H, Goldshtein I, Chodick G, Zigman N. The maccabi glaucoma study: Prevalence and incidence of glaucoma in a large Israeli health maintenance organization. Am J Ophthalmol. 2014,158:402–408.e1. 24794285

16. Yu A, Welge-Luben U. Mechanisms, clinical profile and role of prostaglandin and prostamide analogues in antiglaucomatous therapy. Klin Monbl Augenheilkd. 2013, 230:127–132. doi: 10.1055/s-0032-1327946 23335086

17. Perry CM, McGavin JK, Culy CR, Ibbotson T. Latanoprost: An update of its use in glaucoma and ocular hypertension. Drugs and Aging.2003, 20:597–630. 12795627

18. Li SM, Chen R, Li Y, Yang ZR, Deng QJ, Zhong Z, et al. Meta-analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of Asian populations with chronic angle-closure glaucoma. PLoS One, 2014,9:e96852. 24816233

19. Goldberg I, Cunha-Vaz J, Jakobsen JE, Nordmann JP, Trost E, Sullivan EK, et al. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2001, 10:414–422. 11711841

20. Schehlein EM, Novack GD, Robin AL. New classes of glaucoma medications. Curr Opin Ophthalmol. 2017, 28:161–168. 27828896

21. Liebmann JM, Lee JK. Current therapeutic options and treatments in development for the management of primary open-angle glaucoma. Am J Manag Care. 2017, 23:S279–S292. Available at:

22. Connor AJ, Fraser SG. Glaucoma prescribing trends in England 2000 to 2012. Eye. 2014,28:863–869. 24858531

23. Fajgenbaum M, Ansari E. Prescribing Trends in a Glaucoma Clinic and Adherence to EGS Guidelines: A Retrospective, Non-Interventional, Single-Center UK Study. Adv Ther. 2017,34:2033–2042. 28726170

24. Mansberger SL, Hughes BA, Gordon MO, Spanner SD, Beiser JA, Cioffi GA, et al. Comparison of initial intraocular pressure response with topical β-adrenergic antagonists and prostaglandin analogues in African American and white individuals in the ocular hypertension treatment study. Arch Ophthalmol. 2007,125:454–459. 17420364

25. Conlon R, Saheb H, Ahmed IIK. Glaucoma treatment trends: a review. Can J Ophthalmol. 2017,52:114–124. 28237137

26. Bucolo C, Maria Platania C, Reibaldi M, Bonfiglio V, Longo A, Salomone S, et al. Controversies in Glaucoma: Current Medical Treatment and Drug Development. Curr Pharm Des. 2015, 21:4673–4681. 26350532

27. Tanna AP, Rademaker AW, Stewart WC, Feldman RM. Meta-analysis of the efficacy and safety of α2-adrenergic agonists, β-adrenergic antagonists, and topical carbonic anhydrase inhibitors with prostaglandin analogs. Arch Ophthalmol. 2010,128:825–833. 20625041

28. Musch DC, Lichter PR, Guire KE, Standardi CL. The Collaborative Initial Glaucoma Treatment Study: Study design, methods, and baseline characteristics of enrolled patients. Ophthalmology.1999,106:653–662. 10201583

Článek vyšel v časopise


2020 Číslo 1